Skip to main content

Drug Safety

RT @Janetbirdope: #ClinicalPearl Oral Surveillance chance of having a MACE was highest....you guessed it, in those with

Janet Pope Janetbirdope

1 month ago
#ClinicalPearl Oral Surveillance chance of having a MACE was highest....you guessed it, in those with past MACE events. Some CV risks have different risks ex HTN May have less risk vs high cholesterol @RheumNow @eular_org #EULAR2022 POS0237 https://t.co/kTn4rxMlej
exhibitor.floor.ACR
Bags are packed, ready to go, but wait there’s more abstracts to show. The big news today were the “late breaking” abstracts. This is usually a favorite session of many as this is where the newest…
Axial Spondyloarthritis
This year at EULAR 2022, there were important and interesting topics in Axial Spondyloarthritis (AxSpA). These are my picks of abstracts from the conference. Non-steroidal anti-inflammatory drugs (…
cancer search news magnify
For autoimmune patients with a history of malignancy, the initiation of biologic or targeted synthetic disease modifying agents (bDMARD/tsDMARDs) may provoke concern. While data for biologic…
PSA2L.jpg
At EULAR 2022, I have been looking at topics and presentations in psoriatic arthritis (PsA).  How do PsA patients do on csDMARDs and is the time to switch or escalate to biologics the same as for RA…
RT @synovialjoints: In bDMARD-naive patients with PsA, the 24 week efficacy and safety of BKZ in BE OPTIMAL LB0001 by Mc

Dr. Antoni Chan synovialjoints

1 month ago
In bDMARD-naive patients with PsA, the 24 week efficacy and safety of BKZ in BE OPTIMAL LB0001 by McInnes et al. At Week 16 ACR50 44% BKZ, 10% PBO, ADA 46%. PASI 90 at Week 16, 62% BKZ, PBO 3%, ADA 41% and benefit continued to Week 24 #EULAR2022 @RheumNow https://t.co/LRZoxzM57J
RT @drdavidliew: Rituximab/belimumab patients & COVID vaccination response:
may have had average antibody response
b

David Liew drdavidliew

1 month ago
Rituximab/belimumab patients & COVID vaccination response: may have had average antibody response but there’s still the cellular response to consider too! Not as bad. Still caution++, but when ritux really needed we’ll find a way despite COVID from roundup #EULAR2022 @RheumNow https://t.co/zFr6QI9TOG
×